These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22265873)

  • 1. [Undetectable viral load after the addition of raltegravir in a 36 week pregnant adolescent with high-level HIV viraemia].
    López-Varela E; Rojo-Conejo P; Blázquez-Gamero D; Gonzalez-Granado L
    An Pediatr (Barc); 2012 May; 76(5):296-7. PubMed ID: 22265873
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
    Pinnetti C; Baroncelli S; Villani P; Fantoni M; Tozzi V; De Luca A; Cauda R; Anzidei G; Cusato M; Regazzi M; Floridia M; Tamburrini E
    J Antimicrob Chemother; 2010 Sep; 65(9):2050-2. PubMed ID: 20630894
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report.
    Cha A; Shaikh R; Williams S; Berkowitz LL
    J Int Assoc Provid AIDS Care; 2013; 12(5):312-4. PubMed ID: 23695227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir in pregnancy: a case series presentation.
    Taylor N; Touzeau V; Geit M; Gisinger M; Egle A; Greil R; Rieger A; Zangerle R
    Int J STD AIDS; 2011 Jun; 22(6):358-60. PubMed ID: 21680678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state lopinavir levels in third trimester of pregnancy.
    Lyons F; Lechelt M; De Ruiter A
    AIDS; 2007 May; 21(8):1053-4. PubMed ID: 17457104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancy.
    Renet S; Closon A; Brochet MS; Bussières JF; Boucher M
    J Obstet Gynaecol Can; 2013 Jan; 35(1):68-72. PubMed ID: 23343800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral load in HCV RNA-positive pregnant women.
    Paternoster DM; Santarossa C; Grella P; Palù G; Baldo V; Boccagni P; Floreani A
    Am J Gastroenterol; 2001 Sep; 96(9):2751-4. PubMed ID: 11569706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.
    Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F
    J Infect Dis; 2012 May; 205(10):1520-8. PubMed ID: 22427678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
    Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
    Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen.
    Falasca F; Mazzuti L; DʼEttorre G; Paoletti F; Tripolino O; Serafino S; Antonelli G; Turriziani O
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):e18-20. PubMed ID: 25590274
    [No Abstract]   [Full Text] [Related]  

  • 12. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?
    Read PJ; Mandalia S; Khan P; Harrisson U; Naftalin C; Gilleece Y; Anderson J; Hawkins DA; Taylor GP; de Ruiter A;
    AIDS; 2012 Jun; 26(9):1095-103. PubMed ID: 22441248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 mother-to-child transmission and drug resistance among Brazilian pregnant women with high access to diagnosis and prophylactic measures.
    Alcântara KC; Lins JB; Albuquerque M; Aires LM; Cardoso LP; Minuzzi AL; Stefani MM
    J Clin Virol; 2012 May; 54(1):15-20. PubMed ID: 22317908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment during pregnancy.
    Keiser O; Gayet-Ageron A; Rudin C; Brinkhof MW; Gremlich E; Wunder D; Drack G; Hirschel B; de Tejada BM; ;
    AIDS; 2008 Nov; 22(17):2323-30. PubMed ID: 18981771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
    Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
    J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of HIV-1 viral load in pregnancy.
    Lillo FB; Bucceri AM; Bettini P; Farma E; Boeri E; Mastrorilli E; Rossi G; Vignali M; Varnier OE
    AIDS; 1997 Sep; 11(11):1397-8. PubMed ID: 9302452
    [No Abstract]   [Full Text] [Related]  

  • 18. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
    Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
    J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
    Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.